Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Zambon

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Atherosclerosis Plus|July 3, 2025
Proposed lipidology and preventive cardiology research priorities in Africa; Results of a Delphi surveyAlexander R M Lyons, Frederick J Raal, Brett S Mansfield, et al.
Atherosclerosis|September 24, 2022
Efficacy and safety of lomitapide in familial chylomicronaemia syndromeAngelo B Cefalù, Laura D'Erasmo, Gabriella Iannuzzo, et al.
Pharmacological Research|June 15, 2020
Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular DystrophyStefano C Previtali, Teresa Gidaro, Jordi Díaz-Manera, et al.
The Lancet. Diabetes & Endocrinology|October 19, 2024
Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 studyLuis Masana, Alberto Zambon, Claus Peter Schmitt, et al.
Atherosclerosis|July 1, 2026
Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemiaStella Covino, Alessia Di Costanzo, Alessandra Rossi, et al.
Nature Reviews. Endocrinology|February 6, 2020
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral ObesityRobert Ross, Ian J Neeland, Shizuya Yamashita, et al.
Giornale Italiano Di Cardiologia (2006)|December 27, 2022
[Identifying possible homozygous familial hypercholesterolemia patients: an Italian experts' opinion]Claudio Bilato, Alberto Zambon, Livia Pisciotta, et al.
The Lancet. Diabetes & Endocrinology|July 15, 2019
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statementIan J Neeland, Robert Ross, Jean-Pierre Després, et al.
Atherosclerosis|April 24, 2021
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task ForceMaurizio Averna, Maciej Banach, Eric Bruckert, et al.
European Heart Journal. Digital Health|February 2, 2026
Optimizing lipid-lowering therapy for acute coronary syndrome using a decision support system: insights from a cluster randomized trialChristophe A T Stevens, Jessica Smith, Julia Brandts, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Atherosclerosis Plus|July 3, 2025
Proposed lipidology and preventive cardiology research priorities in Africa; Results of a Delphi surveyAlexander R M Lyons, Frederick J Raal, Brett S Mansfield, et al.
Atherosclerosis|September 24, 2022
Efficacy and safety of lomitapide in familial chylomicronaemia syndromeAngelo B Cefalù, Laura D'Erasmo, Gabriella Iannuzzo, et al.
Pharmacological Research|June 15, 2020
Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular DystrophyStefano C Previtali, Teresa Gidaro, Jordi Díaz-Manera, et al.
The Lancet. Diabetes & Endocrinology|October 19, 2024
Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 studyLuis Masana, Alberto Zambon, Claus Peter Schmitt, et al.
Atherosclerosis|July 1, 2026
Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemiaStella Covino, Alessia Di Costanzo, Alessandra Rossi, et al.
Nature Reviews. Endocrinology|February 6, 2020
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral ObesityRobert Ross, Ian J Neeland, Shizuya Yamashita, et al.
Giornale Italiano Di Cardiologia (2006)|December 27, 2022
[Identifying possible homozygous familial hypercholesterolemia patients: an Italian experts' opinion]Claudio Bilato, Alberto Zambon, Livia Pisciotta, et al.
The Lancet. Diabetes & Endocrinology|July 15, 2019
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statementIan J Neeland, Robert Ross, Jean-Pierre Després, et al.
Atherosclerosis|April 24, 2021
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task ForceMaurizio Averna, Maciej Banach, Eric Bruckert, et al.
European Heart Journal. Digital Health|February 2, 2026
Optimizing lipid-lowering therapy for acute coronary syndrome using a decision support system: insights from a cluster randomized trialChristophe A T Stevens, Jessica Smith, Julia Brandts, et al.
Pageof 10